A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
Infusion therapy providers would be harmed if a federal judge dismisses a lawsuit challenging Medicare’s new drug price ...
“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
Judge Thomas M. Rose of the U.S. District Court for the Southern District of Ohio has withdrawn from a case that could block Medicare's historic drug price negotiation program. Rose disclosed that ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
Analysis-Drugmakers Could Find Sympathetic US Supreme Court in Drug Pricing Lawsuits By Brendan Pierson (Reuters) - Drugmakers challenging a Biden administration program requiring them to ...
